Pearls from the 2024 European Respiratory Congress

Authors

  • Manali Mukherjee, MD Division of Respirology, McMaster University (primary), Hamilton, ON, The Research Institute, St. Joseph’s Healthcare, Hamilton, ON, McMaster Immunology Research Center, McMaster University, Hamilton, ON, Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON

DOI:

https://doi.org/10.58931/cait.2024.4374

Abstract

The European Respiratory Congress 2024, held from September 7th to 11th, 2024, in Vienna, Austria, featured several presentations on airway diseases, interstitial lung diseases, bronchiectasis, and critical care, with a focus on emerging therapies, particularly on asthma and chronic obstructive pulmonary disease (COPD).

Author Biography

Manali Mukherjee, MD, Division of Respirology, McMaster University (primary), Hamilton, ON, The Research Institute, St. Joseph’s Healthcare, Hamilton, ON, McMaster Immunology Research Center, McMaster University, Hamilton, ON, Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON

Dr. Mukherjee is an Assistant Professor in the Division of Respirology, Department of Medicine, and a translational scientist affiliated with the Research Institute of St. Joe's, Hamilton. She has demonstrated expertise in investigating inflammatory mechanisms of chronic respiratory diseases, in particular autoimmunity, response to treatment and development/validation of clinical biomarkers. Her research has identified the presence of localized autoimmune responses in the airways of patients with complex airways disease and determined their pathogenic role in driving disease severity.
Recently, she has identified autoimmune responses in acute-severe COVID and linked autoimmunity with post-acute COVID-19 sequelae (or Long COVID). In the field of respiratory medicine, she published ~65 manuscripts, and in the past 5 years these have accumulated >2500 citations (Google Scholar h-index 24, i10-index 40). Dr. Mukherjee’s research program focuses on “Lung autoimmunity and biomarkers”. She is the past recipient of the Emerging Researcher Award in Allergic Asthma awarded conjointly by the Canadian Institutes of Health Research (CIHR) and the Canadian Asthma, Allergy and Immunology Foundation (CAAIF). Her lab is funded by federal and non-federal sources including CIHR-ICRH and industry. Dr. Mukherjee was recently named the AstraZeneca Chair in Respiratory Diseases (2023-2028).

References

Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662-671. doi:10.1164/rccm.201104-0597OC

Bhalla A, Zhao N, Rivas DD, Ho T, Perez de Llano L, Mukherjee M, et al. Exacerbations of severe asthma while on anti-IL-5 biologics. J Investig Allergol Clin Immunol. 2020;30(5):307-316. doi:10.18176/jiaci.0628

Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879-890. doi:10.1016/s2213-2600(14)70201-2

Brightling CE, Bleecker ER, Panettieri RA, Jr., Bafadhel M, She D, Ward CK, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014;2(11):891-901. doi:10.1016/s2213-2600(14)70187-0

Mukherjee M, Huang C, Venegas-Garrido C, Zhang K, Bhalla A, Ju X, et al. Benralizumab normalizes sputum eosinophilia in severe asthma uncontrolled by Anti-IL-5 antibodies: a single-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med. 2023;208(12):1330-1335. doi:10.1164/rccm.202308-1413LE

Sehmi R, Lim HF, Mukherjee M, Huang C, Radford K, Newbold P, et al. Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma. J Allergy Clin Immunol. 2018;141(4):1529-1532.e1528. doi:10.1016/j.jaci.2018.01.008

Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;2014(9):Cd001288. doi:10.1002/14651858.CD001288.pub4

Ramakrishnan S, Russell REK, Mahmood HR, Krassowska K, Melhorn J, Mwasuku C, et al. Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial. Lancet Respir Med. 2024. doi:10.1016/s2213-2600(24)00299-6

Leung C, Sin DD. A new era in the treatment of acute exacerbations of asthma and COPD. Lancet Respir Med. 2024. doi:10.1016/s2213-2600(24)00323-0

Salter B, Lacy P, Mukherjee M. Biologics in asthma: a molecular perspective to precision medicine. Front Pharmacol. 2021;12:793409. doi:10.3389/fphar.2021.793409

Singh D, Fuhr R, Bird NP, Mole S, Hardes K, Man YL, et al. A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022;88(2):702-712. doi:10.1111/bcp.15002

Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N Engl J Med. 2024. doi:10.1056/NEJMoa2406673

Tavakoli GM, Yazdanpanah N, Rezaei N. Targeting Bruton's tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments. Adv Rheumatol. 2024;64(1):61. doi:10.1186/s42358-024-00401-y

Downloads

Published

2024-12-19

How to Cite

1.
Mukherjee M. Pearls from the 2024 European Respiratory Congress. Can Allergy Immunol Today [Internet]. 2024 Dec. 19 [cited 2024 Dec. 21];4(3):24–28. Available from: https://canadianallergyandimmunologytoday.com/article/view/4-3-Mukherjee

Issue

Volume 4, Issue 3, Fall 2024

Section

Articles